|View printer-friendly version|
|August 29, 2003 4:42 p.m.|
|Teva to Appeal Lower Court Ruling on Weekly Version of FOSAMAX®|
Jerusalem, Israel, August 29, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court in Wilmington, Delaware has issued an opinion following the completion of a trial on U.S. Patent No. 5,994,329, which covers a once-a-week method of administering alendronate sodium, a generic version of Merck & Co.'s Fosamax®. The court found the patent to be valid and that Teva's abbreviated new drug application for the product would infringe the patent.